These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

220 related items for PubMed ID: 18007550

  • 21. Hyponatremia in Cirrhosis: An Update.
    Alukal JJ, John S, Thuluvath PJ.
    Am J Gastroenterol; 2020 Nov; 115(11):1775-1785. PubMed ID: 33156095
    [Abstract] [Full Text] [Related]

  • 22. Complications of cirrhosis. II. Renal and circulatory dysfunction. Lights and shadows in an important clinical problem.
    Arroyo V, Jiménez W.
    J Hepatol; 2000 Nov; 32(1 Suppl):157-70. PubMed ID: 10728802
    [Abstract] [Full Text] [Related]

  • 23. [Hyponatremia in liver cirrhosis: pathogenesis and treatment].
    Guevara M, Ginès P.
    Endocrinol Nutr; 2010 May; 57 Suppl 2():15-21. PubMed ID: 21130958
    [Abstract] [Full Text] [Related]

  • 24. Hyponatremia in cirrhosis: clinical features and management.
    Martín-Llahí M, Guevara M, Ginès P.
    Gastroenterol Clin Biol; 2006 Oct; 30(10):1144-51. PubMed ID: 17075468
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Vasopressin antagonists: role in the management of hyponatremia.
    Yeates KE, Morton AR.
    Am J Nephrol; 2006 Oct; 26(4):348-55. PubMed ID: 16837788
    [Abstract] [Full Text] [Related]

  • 27. Treatment of hyponatremic cirrhosis with ascites resistant to diuretics by urea.
    Decaux G, Mols P, Cauchie P, Flamion B, Delwiche F.
    Nephron; 1986 Oct; 44(4):337-43. PubMed ID: 3796773
    [Abstract] [Full Text] [Related]

  • 28. Vasopressin V2-receptor antagonists: panaceas for hyponatremia?
    Kitiyakara C, Wilcox CS.
    Curr Opin Nephrol Hypertens; 1997 Sep; 6(5):461-7. PubMed ID: 9327205
    [Abstract] [Full Text] [Related]

  • 29. A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial.
    Wong F, Blei AT, Blendis LM, Thuluvath PJ.
    Hepatology; 2003 Jan; 37(1):182-91. PubMed ID: 12500203
    [Abstract] [Full Text] [Related]

  • 30. Effects of a selective vasopressin V2 receptor antagonist, satavaptan, on ascites recurrence after paracentesis in patients with cirrhosis.
    Wong F, Gines P, Watson H, Horsmans Y, Angeli P, Gow P, Minini P, Bernardi M.
    J Hepatol; 2010 Aug; 53(2):283-90. PubMed ID: 20541828
    [Abstract] [Full Text] [Related]

  • 31. [Biological factors influencing response to diuretics in patients with cirrhosis and ascites].
    Lenaerts A, Codden T, Henry JP, Van Cauter J, Meunier JC, Ligny G.
    Gastroenterol Clin Biol; 2001 Mar; 25(3):268-72. PubMed ID: 11395674
    [Abstract] [Full Text] [Related]

  • 32. Amiloride ('MK 870') in patients with ascites due to cirrhosis of the liver.
    Senewiratne B, Sherlock S.
    Lancet; 1968 Jan 20; 1(7534):120-2. PubMed ID: 4169604
    [No Abstract] [Full Text] [Related]

  • 33. Association between the Serum Sodium Levels and the Response to Tolvaptan in Liver Cirrhosis Patients with Ascites and Hyponatremia.
    Hayashi M, Abe K, Fujita M, Okai K, Takahashi A, Ohira H.
    Intern Med; 2018 Sep 01; 57(17):2451-2458. PubMed ID: 29607963
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. [Treatment of ascites in patients with liver cirrhosis without neither hyponatremia nor renal insufficiency. Results of a randomized study comparing diuretics and punctures compensated by albumin].
    Hagège H, Ink O, Ducreux M, Pelletier G, Buffet C, Etienne JP.
    Gastroenterol Clin Biol; 1992 Sep 01; 16(10):751-5. PubMed ID: 1478401
    [Abstract] [Full Text] [Related]

  • 36. Clinical Factors Predicting the Effect of Tolvaptan for Refractory Ascites in Patients with Decompensated Liver Cirrhosis.
    Chishina H, Hagiwara S, Nishida N, Ueshima K, Sakurai T, Ida H, Minami Y, Takita M, Kono M, Minami T, Iwanishi M, Umehara Y, Watanabe T, Komeda Y, Arizumi T, Kudo M.
    Dig Dis; 2016 Sep 01; 34(6):659-664. PubMed ID: 27750234
    [Abstract] [Full Text] [Related]

  • 37. Treatment of ascites in cirrhosis. Diuretics, peritoneovenous shunt, and large-volume paracentesis.
    Arroyo V, Ginès P, Planas R.
    Gastroenterol Clin North Am; 1992 Mar 01; 21(1):237-56. PubMed ID: 1568775
    [Abstract] [Full Text] [Related]

  • 38. Refractory ascites: definition and mechanism.
    Arroyo V, Badalamenti S, Ginès P.
    Minerva Med; 1987 May 31; 78(10):675-80. PubMed ID: 3587714
    [No Abstract] [Full Text] [Related]

  • 39. [Hyponatremia in cirrhosis with ascites].
    Bronzi G, Orlando D, De Feudis L, Delle Monache G, Scudieri M, Sergiacomo L, Bernardi M, Pesa O.
    Minerva Med; 1990 Sep 31; 81(9):591-6. PubMed ID: 2234478
    [Abstract] [Full Text] [Related]

  • 40. Effect of the V1a/V2-AVP receptor antagonist, Conivaptan, on renal water metabolism and systemic hemodynamics in rats with cirrhosis and ascites.
    Fernández-Varo G, Ros J, Cejudo-Martín P, Cano C, Arroyo V, Rivera F, Rodés J, Jiménez W.
    J Hepatol; 2003 Jun 31; 38(6):755-61. PubMed ID: 12763368
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.